ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Reco...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 71; no. 9; pp. 2397 - 2404
Main Authors Maertens, Johan, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stéphane, Cordonnier, Catherine
Format Journal Article
LanguageEnglish
Published England Oxford University Press (OUP) 01.09.2016
Subjects
Antifungal Agents - administration & dosage
Chemoprevention - methods
Hematologic Neoplasms - complications
Hematologic Neoplasms - therapy
Human health and pathology
Humans
Immunocompromised Host
Life Sciences
Pneumonia, Pneumocystis - prevention & control
Stem Cell Transplantation - adverse effects
Transplant Recipients
Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage
Online AccessGet full text
ISSN0305-7453
1460-2091
1460-2091
DOI10.1093/jac/dkw157

Cover

Abstract The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2–3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults (A-II) and children (A-I) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen (B-II). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.
AbstractList The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.
The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2–3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults (A-II) and children (A-I) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen (B-II). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.
The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, \textgreater4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.
Author Donnelly, J. Peter
Matos, Olga
Maschmeyer, Georg
Bretagne, Stéphane
Melchers, Willem J. G.
Lagrou, Katrien
Cordonnier, Catherine
Maertens, Johan
Helweg-Larsen, Jannik
Alanio, Alexandre
Cesaro, Simone
Einsele, Hermann
Hauser, Philippe M.
Author_xml – sequence: 1
  givenname: Johan
  surname: Maertens
  fullname: Maertens, Johan
  organization: Department of Haematology, Acute Leukaemia and Stem Cell Transplantation Unit, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium
– sequence: 2
  givenname: Simone
  surname: Cesaro
  fullname: Cesaro, Simone
  organization: Department of Haematology, Oncoematologia Pediatrica, Policlinico G. B. Rossi, Verona, Italy
– sequence: 3
  givenname: Georg
  surname: Maschmeyer
  fullname: Maschmeyer, Georg
  organization: Department of Haematology, Oncology and Palliative Care, Ernst-von-Bergmann Klinikum, Potsdam, Germany
– sequence: 4
  givenname: Hermann
  surname: Einsele
  fullname: Einsele, Hermann
  organization: Department of Internal Medicine II, Julius Maximilians University, Würzburg, Germany
– sequence: 5
  givenname: J. Peter
  surname: Donnelly
  fullname: Donnelly, J. Peter
  organization: Department of Haematology, Radboud University Medical Center, Nijmegen, The Netherlands
– sequence: 6
  givenname: Alexandre
  surname: Alanio
  fullname: Alanio, Alexandre
  organization: Parasitology-Mycology Laboratory, Groupe Hospitalier Lariboisière Saint-Louis Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Diderot, Sorbonne Paris Cité, and Institut Pasteur, Unité de Mycologie Moléculaire, CNRS URA3012, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France
– sequence: 7
  givenname: Philippe M.
  surname: Hauser
  fullname: Hauser, Philippe M.
  organization: Institute of Microbiology, Lausanne University Hospital and University, Lausanne, Switzerland
– sequence: 8
  givenname: Katrien
  surname: Lagrou
  fullname: Lagrou, Katrien
  organization: Department of Microbiology and Immunology, KU Leuven—University of Leuven, Leuven, Belgium and National Reference Center for Mycosis, Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
– sequence: 9
  givenname: Willem J. G.
  surname: Melchers
  fullname: Melchers, Willem J. G.
  organization: Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands
– sequence: 10
  givenname: Jannik
  surname: Helweg-Larsen
  fullname: Helweg-Larsen, Jannik
  organization: Department of Infectious Diseases, Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark
– sequence: 11
  givenname: Olga
  surname: Matos
  fullname: Matos, Olga
  organization: Medical Parasitology Unit, Group of Opportunistic Protozoa/HIV and Other Protozoa, Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Lisboa, Portugal
– sequence: 12
  givenname: Stéphane
  surname: Bretagne
  fullname: Bretagne, Stéphane
  organization: Parasitology-Mycology Laboratory, Groupe Hospitalier Lariboisière Saint-Louis Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Diderot, Sorbonne Paris Cité, and Institut Pasteur, Unité de Mycologie Moléculaire, CNRS URA3012, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France
– sequence: 13
  givenname: Catherine
  surname: Cordonnier
  fullname: Cordonnier, Catherine
  organization: Department of Haematology, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris-Est-Créteil, Créteil, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27550992$$D View this record in MEDLINE/PubMed
https://pasteur.hal.science/pasteur-01405235$$DView record in HAL
http://kipublications.ki.se/Default.aspx?queryparsed=id:134287363$$DView record from Swedish Publication Index
BookMark eNpt0s1uEzEQB3ALFdG0cOEBkI8Iaak_1tn1sYoKrRQJDnC2vPZs4nTXXmxvor4Fj4zbhCIQJ1ujn__SeOYCnfngAaG3lHykRPKrnTZX9v5ARfMCLWi9JBUjkp6hBeFEVE0t-Dm6SGlHCFmKZfsKnbNGCCIlW6CfN6u7Nd7MzsLgPCTch4inCHvw2fkN_uphHoN5SNklvHMx7ME4h6ensncaO48nnV3hCR9c3uKthlHnMISNM3rAox7cxmtvXAnX3uKUYcQGhgHnqH2aBu0zjiV1egp5jV72ekjw5nReou-fbr6tbqv1l893q-t1ZbiUuWIgue3bjnMubLMUTHNGOtM2PeGNZW3Xy97WRhDaCltbAKhFDU3d9kzUUnT8ElXH3HSAae7UFN2o44MK2qlT6b7cQAnCJGv_-K0e_sK312s16dLVHBWhNRGMiz0t_v3RTzH8mCFlNbr02Lb2EOakaEu5JITTptB3Jzp3I9jn9N9TKuDDEZgYUorQPxNK1OMKqLIC6rgCBZN_sHG5TCj48t9u-N-TX11cuQ8
CitedBy_id crossref_primary_10_1002_mus_27481
crossref_primary_10_1016_j_jtct_2023_11_017
crossref_primary_10_1136_bmjopen_2022_068943
crossref_primary_10_1007_s13555_023_00953_9
crossref_primary_10_1007_s15006_018_0727_2
crossref_primary_10_1142_S2661341722300014
crossref_primary_10_1182_blood_2016_08_734475
crossref_primary_10_1080_17512433_2021_1884067
crossref_primary_10_3166_rea_2018_0056
crossref_primary_10_1097_MOT_0000000000000549
crossref_primary_10_1093_ofid_ofz315
crossref_primary_10_3904_kjim_2018_036
crossref_primary_10_1007_s15033_017_0668_y
crossref_primary_10_1016_S1473_3099_23_00495_4
crossref_primary_10_1038_s41409_018_0391_2
crossref_primary_10_3389_fpubh_2021_680108
crossref_primary_10_1016_j_rmcr_2017_08_012
crossref_primary_10_1080_14656566_2024_2387686
crossref_primary_10_12677_ACRP_2021_92002
crossref_primary_10_3390_jof6040331
crossref_primary_10_1080_14656566_2019_1701654
crossref_primary_10_1016_j_leukres_2022_106926
crossref_primary_10_1159_000487713
crossref_primary_10_1111_myc_13089
crossref_primary_10_3390_jof10040276
crossref_primary_10_1093_jac_dkw580
crossref_primary_10_1177_2049936121989548
crossref_primary_10_3390_cancers14205022
crossref_primary_10_3390_jof4040127
crossref_primary_10_1080_14787210_2019_1573670
crossref_primary_10_3390_jcm14020389
crossref_primary_10_1186_s12879_024_10074_z
crossref_primary_10_1099_jmm_0_000617
crossref_primary_10_1007_s10147_022_02282_x
crossref_primary_10_1016_j_medcli_2019_01_010
crossref_primary_10_1016_j_cmi_2024_03_037
crossref_primary_10_3390_jof7030186
crossref_primary_10_1016_j_infpip_2021_100151
crossref_primary_10_1016_j_medcle_2019_01_018
crossref_primary_10_1136_bcr_2019_232895
crossref_primary_10_1016_j_jtct_2024_05_019
crossref_primary_10_1186_s12885_019_5971_z
crossref_primary_10_1055_a_1735_3864
crossref_primary_10_3390_jof7121058
crossref_primary_10_3390_microorganisms11122839
crossref_primary_10_1097_TP_0000000000003662
crossref_primary_10_1111_myc_13411
crossref_primary_10_2174_0115733963264717231208114248
crossref_primary_10_1016_j_abd_2023_08_004
crossref_primary_10_1111_imj_13668
crossref_primary_10_1007_s10157_019_01772_z
crossref_primary_10_1093_ofid_ofad639
crossref_primary_10_1111_jgh_14832
crossref_primary_10_1007_s12185_021_03281_w
crossref_primary_10_3390_cancers15041344
crossref_primary_10_1002_hon_2540
crossref_primary_10_1016_j_cmi_2021_09_033
crossref_primary_10_3389_fmicb_2017_00700
crossref_primary_10_1111_tid_12802
crossref_primary_10_1007_s10067_024_07149_2
crossref_primary_10_1080_17474086_2023_2290639
crossref_primary_10_2478_raon_2020_0028
crossref_primary_10_3389_fped_2021_782530
crossref_primary_10_3389_fcimb_2020_00224
crossref_primary_10_1093_jac_dkx198
crossref_primary_10_1093_jac_dky286
crossref_primary_10_1016_j_eimce_2019_05_009
crossref_primary_10_1016_j_clml_2020_08_010
crossref_primary_10_1038_s41375_019_0388_x
crossref_primary_10_1007_s15010_017_1005_4
crossref_primary_10_1136_lupus_2021_000551
crossref_primary_10_3390_microorganisms11071694
crossref_primary_10_3390_jof9080812
crossref_primary_10_1007_s10238_024_01503_z
crossref_primary_10_1038_s41409_019_0430_7
crossref_primary_10_1016_j_idc_2019_02_006
crossref_primary_10_1111_myc_12621
crossref_primary_10_1007_s11910_021_01117_y
crossref_primary_10_3389_fped_2022_980234
crossref_primary_10_1080_14656566_2021_1915989
crossref_primary_10_2147_IDR_S233137
crossref_primary_10_3389_fmed_2024_1414092
crossref_primary_10_1016_j_cmi_2018_02_003
crossref_primary_10_1111_tid_13231
crossref_primary_10_3390_jof7080625
crossref_primary_10_1016_j_cmi_2018_02_009
crossref_primary_10_1016_S1773_035X_24_00079_0
crossref_primary_10_1111_tid_13239
crossref_primary_10_1007_s13671_024_00461_9
crossref_primary_10_1007_s11908_021_00753_2
crossref_primary_10_1016_j_mam_2023_101190
crossref_primary_10_1016_j_eimc_2019_05_005
crossref_primary_10_3390_jof8111167
crossref_primary_10_3390_jof9080838
crossref_primary_10_2147_IDR_S444571
crossref_primary_10_3238_PersPneumo_2024_05_17_01
crossref_primary_10_1038_s41572_023_00438_1
crossref_primary_10_1111_ctr_15021
crossref_primary_10_1016_j_ejca_2020_09_013
crossref_primary_10_1002_jha2_1105
crossref_primary_10_1186_s12879_019_3944_0
crossref_primary_10_1007_s12281_024_00482_8
crossref_primary_10_1038_s41598_023_27465_y
crossref_primary_10_1186_s12879_020_05127_y
crossref_primary_10_1016_j_bulcan_2018_08_017
crossref_primary_10_1111_myc_12642
crossref_primary_10_1007_s00277_023_05586_8
crossref_primary_10_1016_j_jtct_2025_03_001
crossref_primary_10_1093_ofid_ofab389
crossref_primary_10_1111_myc_13184
crossref_primary_10_1007_s15010_022_01790_2
crossref_primary_10_1016_j_jhin_2023_03_003
crossref_primary_10_1016_j_lanepe_2022_100400
crossref_primary_10_1007_s00277_021_04438_7
crossref_primary_10_1080_14787210_2017_1305887
crossref_primary_10_1111_tid_12968
crossref_primary_10_1093_ofid_ofae363
crossref_primary_10_1016_S2352_3026_21_00283_0
crossref_primary_10_1093_infdis_jiaa731
crossref_primary_10_7759_cureus_52050
crossref_primary_10_2147_IDR_S358483
crossref_primary_10_1016_j_intimp_2022_109636
crossref_primary_10_3390_diagnostics15070793
crossref_primary_10_1007_s12185_022_03517_3
crossref_primary_10_3389_fonc_2022_874117
crossref_primary_10_1007_s11046_019_00408_w
crossref_primary_10_3390_jcm10010164
crossref_primary_10_1111_crj_13463
crossref_primary_10_1016_j_idc_2020_02_002
crossref_primary_10_1159_000487439
crossref_primary_10_1128_cmr_00101_22
crossref_primary_10_3390_jof7090747
crossref_primary_10_1016_j_jcyt_2019_11_002
crossref_primary_10_1111_tid_13155
crossref_primary_10_3389_fcimb_2024_1210857
crossref_primary_10_1002_pbc_26453
crossref_primary_10_1007_s11560_020_00433_7
crossref_primary_10_1182_bloodadvances_2019000499
crossref_primary_10_1080_14787210_2019_1671823
crossref_primary_10_1111_tid_13955
crossref_primary_10_3389_fcimb_2021_784236
crossref_primary_10_1038_s41409_017_0024_1
crossref_primary_10_1016_j_mmifmc_2024_09_007
crossref_primary_10_1016_j_bbmt_2017_04_026
crossref_primary_10_3390_life13061272
crossref_primary_10_1080_10428194_2017_1357170
crossref_primary_10_1016_j_idc_2017_11_003
crossref_primary_10_1007_s12281_018_0311_3
crossref_primary_10_3138_jammi_2024_0013
crossref_primary_10_1080_14787210_2017_1364991
crossref_primary_10_1016_j_retram_2019_05_001
crossref_primary_10_1136_bcr_2022_249346
crossref_primary_10_1093_rap_rkaa029
crossref_primary_10_3390_jof9040406
crossref_primary_10_3389_fpubh_2019_00275
crossref_primary_10_1590_2175_8239_jbn_2018_0254
crossref_primary_10_1093_jac_dkw155
crossref_primary_10_1093_jac_dkw156
crossref_primary_10_1093_jac_dkw158
crossref_primary_10_1007_s10096_018_3425_1
crossref_primary_10_1007_s11654_019_0133_y
crossref_primary_10_1016_j_waojou_2023_100856
crossref_primary_10_1002_pbc_26558
crossref_primary_10_1016_j_chest_2020_05_558
crossref_primary_10_1186_s13075_020_02167_2
crossref_primary_10_1111_jdv_14144
crossref_primary_10_1111_ajco_14156
crossref_primary_10_3389_fped_2021_705179
crossref_primary_10_1016_S1245_1789_23_48527_7
crossref_primary_10_1002_pbc_31201
crossref_primary_10_15690_vsp_v17i2_1877
crossref_primary_10_1016_j_ajem_2024_11_073
crossref_primary_10_1136_archdischild_2020_319997
crossref_primary_10_1128_aac_00833_22
crossref_primary_10_1016_S1877_1203_18_30077_6
crossref_primary_10_1111_ped_15593
crossref_primary_10_1016_j_heliyon_2024_e39302
crossref_primary_10_1038_s41598_018_26743_4
crossref_primary_10_1080_17476348_2019_1557049
crossref_primary_10_1097_MD_0000000000033399
crossref_primary_10_1007_s00277_018_3562_8
crossref_primary_10_1007_s00277_023_05517_7
crossref_primary_10_1016_j_jiac_2019_01_005
crossref_primary_10_1016_j_jiph_2023_03_022
crossref_primary_10_1016_j_riam_2019_09_001
crossref_primary_10_1111_bjh_19382
crossref_primary_10_1080_10428194_2023_2252945
crossref_primary_10_1007_s00761_017_0223_9
crossref_primary_10_1007_s10067_021_05660_4
crossref_primary_10_1093_mmy_myab065
crossref_primary_10_1111_tid_14169
crossref_primary_10_1016_j_ijid_2022_05_024
crossref_primary_10_1016_j_ijid_2024_107059
crossref_primary_10_1093_jac_dkx450
crossref_primary_10_1182_blood_2023021414
crossref_primary_10_1016_j_clml_2020_06_021
crossref_primary_10_3238_PersInfek_2020_09_11_07
crossref_primary_10_1111_ejh_14133
crossref_primary_10_1080_13506129_2025_2463678
crossref_primary_10_1186_s12879_024_09893_x
crossref_primary_10_1097_MD_0000000000018696
crossref_primary_10_1182_blood_2019003687
crossref_primary_10_1080_17474086_2020_1696185
crossref_primary_10_1016_j_cmi_2018_01_030
crossref_primary_10_1016_j_ijid_2017_02_010
crossref_primary_10_1002_acr_24584
crossref_primary_10_1093_ckj_sfx038
crossref_primary_10_1080_14737140_2022_2131544
crossref_primary_10_3390_cancers15225381
crossref_primary_10_1016_j_jinf_2024_106162
crossref_primary_10_1128_AAC_01992_20
crossref_primary_10_1016_j_cmi_2023_04_015
Cites_doi 10.1111/j.1600-0609.2011.01695.x
10.1111/j.1399-3046.2007.00891.x
10.1200/JCO.1994.12.2.258
10.1128/JCM.40.4.1555-1557.2002
10.1002/cncr.25904
10.3201/eid0901.020141
10.1002/pbc.21287
10.4065/82.9.1052
10.1056/NEJM198706253162604
10.1002/cncr.22562
10.1016/S0022-3476(05)83513-9
10.1002/pbc.20164
10.1016/j.jpeds.2013.10.021
10.1038/sj.bmt.1702004
10.1056/NEJM197712292972602
10.1200/JCO.1994.12.1.136
10.1016/S1083-8791(00)70050-4
10.1056/NEJM199812243392604
10.1371/journal.pone.0070619
10.1097/MPH.0b013e3181fd6fca
10.1002/ppul.1950180406
10.1002/pbc.21774
10.1016/j.bbmt.2005.04.011
10.3109/1040841X.2010.484001
10.1002/pbc.21202
10.1034/j.1399-3062.2002.t01-1-00008.x
10.1128/JCM.38.4.1536-1538.2000
10.1086/383150
10.1542/peds.2006-1360
10.1016/j.transproceed.2009.03.004
10.1097/00006454-199905000-00007
10.1086/514626
10.1159/000040719
10.1097/INF.0b013e3181f30eb6
10.1128/AAC.42.6.1315
10.1093/jac/dkw155
10.1086/314893
10.1086/313509
10.1371/journal.pone.0008524
ContentType Journal Article
Contributor Slavin, Monica
Matos, Olga
Maschmeyer, Georg
Orasch, Christina
Pagano, Livio
Agrawal, Samir
Castagnola, Elio
Akova, Murat
Mikulska, Malgorzata
Racil, Zdenek
Sinko, Janos
Hirsch, Hans
Maertens, Johan
Helweg-Larsen, Jannick
Munoz, Patricia
Ward, Katherine
Klyasova, Galina
Styczynski, Jan
Kouba, Michal
Ljungman, Per
Tweddle, Lorraine
Girmenia, Corrado
Engelhard, Dan
Donnelly, Peter
Roilides, Emmanuel
Calandra, Thierry
Wood, Craig
Cordonnier, Catherine
Lagrou, Katrien
Tissot, Frederic
Drgona, Lubos
Cornely, Oliver
van Boemmel, Florian
Mallet, Vincent
Viscoli, Claudio
Penack, Olaf
Blennow, Ola
Bretagne, Stéphane
Pagliuca, Antonio
Aljurf, Mahmoud
von Lilienfeld-Toal, Marie
Melchers, Willem
Marchetti, Oscar
Rizzi-Puechal, Valérie
Kibbler, Christopher
Duarte, Rafael
Hubacek, Petr
Alanio, Alexandre
Averbuch, Dina
Hauser, Philippe
Herbrecht, Raoul
Pettrikos, George
Ribaud, Patricia
Skiada, Anna
Kullberg, Bart-Jan
De La Camara, Rafael
Hargreaves, Ruth
Berg, Thomas
Cesaro, Simone
Brüggemann, Roger
Einsele, Hermann
Contributor_xml – sequence: 1
  givenname: Samir
  surname: Agrawal
  fullname: Agrawal, Samir
– sequence: 2
  givenname: Murat
  surname: Akova
  fullname: Akova, Murat
– sequence: 3
  givenname: Alexandre
  surname: Alanio
  fullname: Alanio, Alexandre
– sequence: 4
  givenname: Mahmoud
  surname: Aljurf
  fullname: Aljurf, Mahmoud
– sequence: 5
  givenname: Dina
  surname: Averbuch
  fullname: Averbuch, Dina
– sequence: 6
  givenname: Thomas
  surname: Berg
  fullname: Berg, Thomas
– sequence: 7
  givenname: Ola
  surname: Blennow
  fullname: Blennow, Ola
– sequence: 8
  givenname: Stéphane
  surname: Bretagne
  fullname: Bretagne, Stéphane
– sequence: 9
  givenname: Roger
  surname: Brüggemann
  fullname: Brüggemann, Roger
– sequence: 10
  givenname: Thierry
  surname: Calandra
  fullname: Calandra, Thierry
– sequence: 11
  givenname: Elio
  surname: Castagnola
  fullname: Castagnola, Elio
– sequence: 12
  givenname: Simone
  surname: Cesaro
  fullname: Cesaro, Simone
– sequence: 13
  givenname: Catherine
  surname: Cordonnier
  fullname: Cordonnier, Catherine
– sequence: 14
  givenname: Oliver
  surname: Cornely
  fullname: Cornely, Oliver
– sequence: 15
  givenname: Rafael
  surname: De La Camara
  fullname: De La Camara, Rafael
– sequence: 16
  givenname: Peter
  surname: Donnelly
  fullname: Donnelly, Peter
– sequence: 17
  givenname: Lubos
  surname: Drgona
  fullname: Drgona, Lubos
– sequence: 18
  givenname: Rafael
  surname: Duarte
  fullname: Duarte, Rafael
– sequence: 19
  givenname: Hermann
  surname: Einsele
  fullname: Einsele, Hermann
– sequence: 20
  givenname: Dan
  surname: Engelhard
  fullname: Engelhard, Dan
– sequence: 21
  givenname: Corrado
  surname: Girmenia
  fullname: Girmenia, Corrado
– sequence: 22
  givenname: Ruth
  surname: Hargreaves
  fullname: Hargreaves, Ruth
– sequence: 23
  givenname: Philippe
  surname: Hauser
  fullname: Hauser, Philippe
– sequence: 24
  givenname: Jannick
  surname: Helweg-Larsen
  fullname: Helweg-Larsen, Jannick
– sequence: 25
  givenname: Raoul
  surname: Herbrecht
  fullname: Herbrecht, Raoul
– sequence: 26
  givenname: Hans
  surname: Hirsch
  fullname: Hirsch, Hans
– sequence: 27
  givenname: Petr
  surname: Hubacek
  fullname: Hubacek, Petr
– sequence: 28
  givenname: Christopher
  surname: Kibbler
  fullname: Kibbler, Christopher
– sequence: 29
  givenname: Galina
  surname: Klyasova
  fullname: Klyasova, Galina
– sequence: 30
  givenname: Michal
  surname: Kouba
  fullname: Kouba, Michal
– sequence: 31
  givenname: Bart-Jan
  surname: Kullberg
  fullname: Kullberg, Bart-Jan
– sequence: 32
  givenname: Katrien
  surname: Lagrou
  fullname: Lagrou, Katrien
– sequence: 33
  givenname: Per
  surname: Ljungman
  fullname: Ljungman, Per
– sequence: 34
  givenname: Johan
  surname: Maertens
  fullname: Maertens, Johan
– sequence: 35
  givenname: Vincent
  surname: Mallet
  fullname: Mallet, Vincent
– sequence: 36
  givenname: Oscar
  surname: Marchetti
  fullname: Marchetti, Oscar
– sequence: 37
  givenname: Georg
  surname: Maschmeyer
  fullname: Maschmeyer, Georg
– sequence: 38
  givenname: Olga
  surname: Matos
  fullname: Matos, Olga
– sequence: 39
  givenname: Willem
  surname: Melchers
  fullname: Melchers, Willem
– sequence: 40
  givenname: Malgorzata
  surname: Mikulska
  fullname: Mikulska, Malgorzata
– sequence: 41
  givenname: Patricia
  surname: Munoz
  fullname: Munoz, Patricia
– sequence: 42
  givenname: Christina
  surname: Orasch
  fullname: Orasch, Christina
– sequence: 43
  givenname: Livio
  surname: Pagano
  fullname: Pagano, Livio
– sequence: 44
  givenname: Antonio
  surname: Pagliuca
  fullname: Pagliuca, Antonio
– sequence: 45
  givenname: Olaf
  surname: Penack
  fullname: Penack, Olaf
– sequence: 46
  givenname: George
  surname: Pettrikos
  fullname: Pettrikos, George
– sequence: 47
  givenname: Zdenek
  surname: Racil
  fullname: Racil, Zdenek
– sequence: 48
  givenname: Patricia
  surname: Ribaud
  fullname: Ribaud, Patricia
– sequence: 49
  givenname: Valérie
  surname: Rizzi-Puechal
  fullname: Rizzi-Puechal, Valérie
– sequence: 50
  givenname: Emmanuel
  surname: Roilides
  fullname: Roilides, Emmanuel
– sequence: 51
  givenname: Janos
  surname: Sinko
  fullname: Sinko, Janos
– sequence: 52
  givenname: Anna
  surname: Skiada
  fullname: Skiada, Anna
– sequence: 53
  givenname: Monica
  surname: Slavin
  fullname: Slavin, Monica
– sequence: 54
  givenname: Jan
  surname: Styczynski
  fullname: Styczynski, Jan
– sequence: 55
  givenname: Frederic
  surname: Tissot
  fullname: Tissot, Frederic
– sequence: 56
  givenname: Lorraine
  surname: Tweddle
  fullname: Tweddle, Lorraine
– sequence: 57
  givenname: Florian
  surname: van Boemmel
  fullname: van Boemmel, Florian
– sequence: 58
  givenname: Marie
  surname: von Lilienfeld-Toal
  fullname: von Lilienfeld-Toal, Marie
– sequence: 59
  givenname: Claudio
  surname: Viscoli
  fullname: Viscoli, Claudio
– sequence: 60
  givenname: Katherine
  surname: Ward
  fullname: Ward, Katherine
– sequence: 61
  givenname: Craig
  surname: Wood
  fullname: Wood, Craig
Copyright The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
CorporateAuthor 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN)
CorporateAuthor_xml – name: 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN)
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
1XC
ADTPV
AOWAS
DOI 10.1093/jac/dkw157
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Hyper Article en Ligne (HAL)
SwePub
SwePub Articles
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2091
EndPage 2404
ExternalDocumentID oai_swepub_ki_se_502928
oai_HAL_pasteur_01405235v1
27550992
10_1093_jac_dkw157
Genre Research Support, Non-U.S. Gov't
Journal Article
Practice Guideline
GroupedDBID ---
-E4
.2P
.I3
.XZ
.ZR
0R~
18M
1TH
29J
2WC
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
AAYXX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABPQP
ABPTD
ABQLI
ABQNK
ABVGC
ABWST
ABXVV
ABZBJ
ACCCW
ACGFO
ACGFS
ACIWK
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AGINJ
AGKEF
AGORE
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CITATION
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECGQY
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HH5
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O9-
OAUYM
OAWHX
OBS
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
ROL
ROX
ROZ
RUSNO
RW1
RXO
TCURE
TEORI
TJX
TMA
TR2
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
~91
.GJ
3O-
6.Y
AAPGJ
AAWDT
ABNGD
ABQTQ
ABSAR
ABSMQ
ACFRR
ACPQN
ACZBC
ADJQC
ADRIX
AEHUL
AEKPW
AFFNX
AFFQV
AFSHK
AFXEN
AFYAG
AGKRT
AGMDO
AI.
APJGH
AQDSO
AQKUS
ASPBG
ATTQO
AVWKF
AZFZN
BZKNY
CAG
CGR
COF
CUY
CVF
ECM
EIF
EIHJH
FEDTE
HVGLF
J5H
M49
MBLQV
NPM
NTWIH
O0~
O~Y
PB-
QBD
RHF
RNI
RZF
RZO
UCJ
VH1
Y6R
ZGI
ZXP
~A~
7X8
1XC
ACUKT
ACVCV
ADMTO
AGQPQ
AHGBF
AJDVS
AVNTJ
OBFPC
ADTPV
AOWAS
ID FETCH-LOGICAL-c399t-2e93df8b3335d7652a320bc87f037d28bf9fd4c50185d4deee454e748f25495b3
ISSN 0305-7453
1460-2091
IngestDate Mon Sep 01 03:31:44 EDT 2025
Fri Jul 18 06:20:41 EDT 2025
Fri Jul 11 15:38:06 EDT 2025
Wed Feb 19 02:43:36 EST 2025
Thu Apr 24 23:01:55 EDT 2025
Tue Jul 01 03:17:14 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
License The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c399t-2e93df8b3335d7652a320bc87f037d28bf9fd4c50185d4deee454e748f25495b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ORCID 0000-0001-9726-3082
0000-0001-6870-3800
0000-0002-8698-9547
0000-0003-4257-5980
0000-0002-7680-0819
OpenAccessLink https://academic.oup.com/jac/article-pdf/71/9/2397/30069065/dkw157.pdf
PMID 27550992
PQID 1813900317
PQPubID 23479
PageCount 8
ParticipantIDs swepub_primary_oai_swepub_ki_se_502928
hal_primary_oai_HAL_pasteur_01405235v1
proquest_miscellaneous_1813900317
pubmed_primary_27550992
crossref_primary_10_1093_jac_dkw157
crossref_citationtrail_10_1093_jac_dkw157
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-09-01
PublicationDateYYYYMMDD 2016-09-01
PublicationDate_xml – month: 09
  year: 2016
  text: 2016-09-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of antimicrobial chemotherapy
PublicationTitleAlternate J Antimicrob Chemother
PublicationYear 2016
Publisher Oxford University Press (OUP)
Publisher_xml – name: Oxford University Press (OUP)
References Cheval (2019092716314442200_DKW157C35) 1993; 53
Garcia de la Fuente (2019092716314442200_DKW157C42) 2010; 29
Hughes (2019092716314442200_DKW157C23) 1977; 297
Manoloff (2019092716314442200_DKW157C2) 2003; 9
Miller (2019092716314442200_DKW157C3) 2002; 40
Hughes (2019092716314442200_DKW157C13) 1998; 27
Green (2019092716314442200_DKW157C5) 2007; 82
Derouin (2019092716314442200_DKW157C44) 2001; 2
Lobo (2019092716314442200_DKW157C22) 2013; 8
Vasconcelles (2019092716314442200_DKW157C11) 2000; 6
Agrawal (2019092716314442200_DKW157C27) 2011; 33
Vargas (2019092716314442200_DKW157C4) 2000; 38
Cushion (2019092716314442200_DKW157C21) 2010; 5
Hughes (2019092716314442200_DKW157C24) 1987; 316
Kim (2019092716314442200_DKW157C30) 2008; 50
Mahon (2019092716314442200_DKW157C8) 1991; 8
Prasad (2019092716314442200_DKW157C31) 2008; 50
Marras (2019092716314442200_DKW157C12) 2002; 4
Machado (2019092716314442200_DKW157C10) 1998; 99
Souza (2019092716314442200_DKW157C14) 1999; 29
O'Sullivan (2019092716314442200_DKW157C33) 1994; 18
Hughes (2019092716314442200_DKW157C38) 1998; 42
Weintrub (2019092716314442200_DKW157C36) 1993; 122
Williams (2019092716314442200_DKW157C41) 2005; 44
Levinsen (2019092716314442200_DKW157C26) 2012; 88
Caselli (2019092716314442200_DKW157C25) 2013; 164
Madden (2019092716314442200_DKW157C37) 2007; 109
Di Cocco (2019092716314442200_DKW157C7) 2009; 41
Green (2019092716314442200_DKW157C6) 2007
McIntosh (2019092716314442200_DKW157C39) 1999; 18
Cordonnier (2019092716314442200_DKW157C1) 2016; 71
Colby (2019092716314442200_DKW157C19) 1999; 24
Chan (2019092716314442200_DKW157C17) 1999; 180
Finkelman (2019092716314442200_DKW157C20) 2010; 36
El-Sadr (2019092716314442200_DKW157C16) 1998; 339
Esbenshade (2019092716314442200_DKW157C40) 2011; 117
Megged (2019092716314442200_DKW157C43) 2008; 12
Link (2019092716314442200_DKW157C9) 1993; 11
Rodriguez (2019092716314442200_DKW157C18) 2004; 38
Ohata (2019092716314442200_DKW157C29) 2009; 52
Weinthal (2019092716314442200_DKW157C34) 1994; 12
Mustafa (2019092716314442200_DKW157C32) 1994; 12
Lindemulder (2019092716314442200_DKW157C28) 2007; 120
Sangiolo (2019092716314442200_DKW157C15) 2005; 11
References_xml – volume: 88
  start-page: 78
  year: 2012
  ident: 2019092716314442200_DKW157C26
  article-title: Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia
  publication-title: Eur J Haematol
  doi: 10.1111/j.1600-0609.2011.01695.x
– volume: 12
  start-page: 902
  year: 2008
  ident: 2019092716314442200_DKW157C43
  article-title: Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation
  publication-title: Pediatr Transplant
  doi: 10.1111/j.1399-3046.2007.00891.x
– volume: 12
  start-page: 258
  year: 1994
  ident: 2019092716314442200_DKW157C32
  article-title: Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1994.12.2.258
– volume: 40
  start-page: 1555
  year: 2002
  ident: 2019092716314442200_DKW157C3
  article-title: Probable mother-to-infant transmission of Pneumocystis carinii f. sp. hominis infection
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.40.4.1555-1557.2002
– volume: 117
  start-page: 3485
  year: 2011
  ident: 2019092716314442200_DKW157C40
  article-title: Dapsone-induced methemoglobinemia: a dose-related occurrence?
  publication-title: Cancer
  doi: 10.1002/cncr.25904
– volume: 9
  start-page: 132
  year: 2003
  ident: 2019092716314442200_DKW157C2
  article-title: Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid0901.020141
– start-page: CD005590
  year: 2007
  ident: 2019092716314442200_DKW157C6
  article-title: Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients
  publication-title: Cochrane Database Syst Rev
– volume: 50
  start-page: 779
  year: 2008
  ident: 2019092716314442200_DKW157C30
  article-title: Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21287
– volume: 82
  start-page: 1052
  year: 2007
  ident: 2019092716314442200_DKW157C5
  article-title: Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials
  publication-title: Mayo Clin Proc
  doi: 10.4065/82.9.1052
– volume: 316
  start-page: 1627
  year: 1987
  ident: 2019092716314442200_DKW157C24
  article-title: Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198706253162604
– volume: 11
  start-page: 403
  year: 1993
  ident: 2019092716314442200_DKW157C9
  article-title: Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT
  publication-title: Bone Marrow Transplant
– volume: 109
  start-page: 1654
  year: 2007
  ident: 2019092716314442200_DKW157C37
  article-title: Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia
  publication-title: Cancer
  doi: 10.1002/cncr.22562
– volume: 122
  start-page: 163
  year: 1993
  ident: 2019092716314442200_DKW157C36
  article-title: Failure of intravenous pentamidine prophylaxis for Pneumocystis carinii pneumonia
  publication-title: J Pediatr
  doi: 10.1016/S0022-3476(05)83513-9
– volume: 44
  start-page: 55
  year: 2005
  ident: 2019092716314442200_DKW157C41
  article-title: Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.20164
– volume: 164
  start-page: 389
  year: 2013
  ident: 2019092716314442200_DKW157C25
  article-title: Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer
  publication-title: J Pediatr
  doi: 10.1016/j.jpeds.2013.10.021
– volume: 8
  start-page: 64
  year: 1991
  ident: 2019092716314442200_DKW157C8
  article-title: Possible prevention of Pneumocystis carinii pneumonia by pentamidine aerosol after bone marrow transplantation
  publication-title: Bone Marrow Transplant
– volume: 24
  start-page: 897
  year: 1999
  ident: 2019092716314442200_DKW157C19
  article-title: A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1702004
– volume: 297
  start-page: 1419
  year: 1977
  ident: 2019092716314442200_DKW157C23
  article-title: Successful chemoprophylaxis for Pneumocystis carinii pneumonitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197712292972602
– volume: 12
  start-page: 136
  year: 1994
  ident: 2019092716314442200_DKW157C34
  article-title: Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1994.12.1.136
– volume: 6
  start-page: 35
  year: 2000
  ident: 2019092716314442200_DKW157C11
  article-title: Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/S1083-8791(00)70050-4
– volume: 339
  start-page: 1889
  year: 1998
  ident: 2019092716314442200_DKW157C16
  article-title: Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199812243392604
– volume: 8
  start-page: e70619
  year: 2013
  ident: 2019092716314442200_DKW157C22
  article-title: Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0070619
– volume: 33
  start-page: e1
  year: 2011
  ident: 2019092716314442200_DKW157C27
  article-title: Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0b013e3181fd6fca
– volume: 18
  start-page: 228
  year: 1994
  ident: 2019092716314442200_DKW157C33
  article-title: The use of aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in children with leukemia
  publication-title: Pediatr Pulmonol
  doi: 10.1002/ppul.1950180406
– volume: 52
  start-page: 142
  year: 2009
  ident: 2019092716314442200_DKW157C29
  article-title: Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21774
– volume: 53
  start-page: 225
  year: 1993
  ident: 2019092716314442200_DKW157C35
  article-title: Principal clinical manifestations during the course of disease caused by the human immunodeficiency virus (HIV) in Pointe-Noire (Republic of Congo). (307 cases hospitalized during 2 years at the medical service of the Regional Hospital of the Army)
  publication-title: Med Trop (Mars)
– volume: 2
  start-page: 1368
  year: 2001
  ident: 2019092716314442200_DKW157C44
  article-title: Anti-toxoplasmosis drugs
  publication-title: Curr Opin Investig Drugs
– volume: 11
  start-page: 521
  year: 2005
  ident: 2019092716314442200_DKW157C15
  article-title: Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case–control study
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2005.04.011
– volume: 36
  start-page: 271
  year: 2010
  ident: 2019092716314442200_DKW157C20
  article-title: Pneumocystis jirovecii infection: cell wall (1-3)-β-d-glucan biology and diagnostic utility
  publication-title: Crit Rev Microbiol
  doi: 10.3109/1040841X.2010.484001
– volume: 50
  start-page: 896
  year: 2008
  ident: 2019092716314442200_DKW157C31
  article-title: Pneumocystis pneumonia in children receiving chemotherapy
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21202
– volume: 4
  start-page: 66
  year: 2002
  ident: 2019092716314442200_DKW157C12
  article-title: Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation
  publication-title: Transpl Infect Dis
  doi: 10.1034/j.1399-3062.2002.t01-1-00008.x
– volume: 38
  start-page: 1536
  year: 2000
  ident: 2019092716314442200_DKW157C4
  article-title: Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.38.4.1536-1538.2000
– volume: 38
  start-page: e76
  year: 2004
  ident: 2019092716314442200_DKW157C18
  article-title: Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients
  publication-title: Clin Infect Dis
  doi: 10.1086/383150
– volume: 120
  start-page: e47
  year: 2007
  ident: 2019092716314442200_DKW157C28
  article-title: Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients
  publication-title: Pediatrics
  doi: 10.1542/peds.2006-1360
– volume: 41
  start-page: 1201
  year: 2009
  ident: 2019092716314442200_DKW157C7
  article-title: A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2009.03.004
– volume: 18
  start-page: 432
  year: 1999
  ident: 2019092716314442200_DKW157C39
  article-title: Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-199905000-00007
– volume: 27
  start-page: 191
  year: 1998
  ident: 2019092716314442200_DKW157C13
  article-title: Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review
  publication-title: Clin Infect Dis
  doi: 10.1086/514626
– volume: 99
  start-page: 54
  year: 1998
  ident: 2019092716314442200_DKW157C10
  article-title: Primary Pneumocystis carinii prophylaxis with aerosolized pentamidine after bone marrow transplantation
  publication-title: Acta Haematol
  doi: 10.1159/000040719
– volume: 29
  start-page: 1059
  year: 2010
  ident: 2019092716314442200_DKW157C42
  article-title: Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0b013e3181f30eb6
– volume: 42
  start-page: 1315
  year: 1998
  ident: 2019092716314442200_DKW157C38
  article-title: Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.42.6.1315
– volume: 71
  start-page: 2379
  year: 2016
  ident: 2019092716314442200_DKW157C1
  article-title: Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkw155
– volume: 180
  start-page: 369
  year: 1999
  ident: 2019092716314442200_DKW157C17
  article-title: Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides
  publication-title: J Infect Dis
  doi: 10.1086/314893
– volume: 29
  start-page: 1467
  year: 1999
  ident: 2019092716314442200_DKW157C14
  article-title: High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis
  publication-title: Clin Infect Dis
  doi: 10.1086/313509
– volume: 5
  start-page: e8524
  year: 2010
  ident: 2019092716314442200_DKW157C21
  article-title: Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0008524
SSID ssj0006568
Score 2.595239
SecondaryResourceType review_article
Snippet The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis...
SourceID swepub
hal
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2397
SubjectTerms Antifungal Agents - administration & dosage
Chemoprevention - methods
Hematologic Neoplasms - complications
Hematologic Neoplasms - therapy
Human health and pathology
Humans
Immunocompromised Host
Life Sciences
Pneumonia, Pneumocystis - prevention & control
Stem Cell Transplantation - adverse effects
Transplant Recipients
Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage
Title ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
URI https://www.ncbi.nlm.nih.gov/pubmed/27550992
https://www.proquest.com/docview/1813900317
https://pasteur.hal.science/pasteur-01405235
http://kipublications.ki.se/Default.aspx?queryparsed=id:134287363
Volume 71
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1bb9MwFMetbkiIFwTjVm4yAlVCXbYmjuv4caoKBQ3Uh07qWxTH7mVb06iXofLMB-Ajc06cJinrw-DFiizXjnJ-cU_sc_4m5APj2gTKlU7AGHN8ziJHRi3f0bEWvhZR5OlM7fN7u3fhfx3yYa32qxK1tF6pk_jn3ryS_7Eq1IFdMUv2HyxbdAoVcA32hRIsDOWdbNztfDlvjteoVIXR61nIYJprMiXjZj8x69k83sBbvGxeThfzG1SyaKZZNWZjlbqqeZLbJEIJ12I-nIGTPrbn91opZ1R9buJaPx4tkSzTa7BLE_Ux0ulWE2qPpwuNprNppviEaiQTM8vTvioRyGaBofQ7-1Qds4xsFk5l3Rw-xmdmYzkrjgXrTjGv3pS5Fvkyhtsu4rSK9K0Wd4RvlYO3U7NwKwjK6jzLbFTvrT8AK451GcVQ6qsfrlW_3iOpbXVhwyu4MiFvedILDsg9T4hss__zsAwUatuEyuIGtyK3kp3COKd2lB235mCCQbW3v1j-kqPNXJjBI_Iwtwg9syA9JjWTHJH73_LoiiPS6Fsd880xHZRpectj2qD9UuF884T8RvBoCR4F8GgJHq2CRwvwaAEenSZ0Cx5F8OgueLQKHgXwKIJHETxagkdL8J6Si0_dQafn5Ed7ODF4xCvHM5LpUaBgguBatLkXMa-l4kCMWkxoL1AjOdJ-jGqTXPvaGONz3wg_GOGCBlfsGTlM5ol5QagGB1yptooNb8MvlFSBiKSSMnIDEUhRJx-3lgnjXPcej1-5Dm38BQvBiqG1Yp28L9qmVu1lb6sGGLhogDT1zs7DNIJnsV6EuGbBPcZv3Dp5t2UghFkbn1KUmPl6GYJfzXAPwYXOnls4iv48wcGLlx4Mk0NaHWkPty_v2vAVeVC-eq_J4WqxNm_Ap16ptxnyfwA7Etzm
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ECIL+guidelines+for+preventing+Pneumocystis+jirovecii+pneumonia+in+patients+with+haematological+malignancies+and+stem+cell+transplant+recipients&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Maertens%2C+J&rft.au=Cesaro%2C+S&rft.au=Maschmeyer%2C+G&rft.au=Einsele%2C+H&rft.date=2016-09-01&rft.issn=0305-7453&rft.volume=71&rft.issue=9&rft.spage=2397&rft_id=info:doi/10.1093%2Fjac%2Fdkw157&rft.externalDocID=oai_swepub_ki_se_502928
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon